Dll4 blockade potentiates the anti-tumor Effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Miles, Kiersten Marie ^a   Seshadri, Mukund ^b   Ciamporcero, Eric ^c   Adelaiye, Remi ^b   Gillard, Bryan ^b   Sotomayor, Paula ^b   Attwood, Kristopher ^b   Shen, Li ^a   Conroy, Dylan ^b   Kuhnert, Frank ^d   Lalani, Alshad S ^d   Thurston, Gavin ^d   Pili, Roberto ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NOTCH LIGAND DELTA LIKE 4 PROTEIN; NOTCH RECEPTOR; REGN 1035; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; DLL4 PROTEIN, HUMAN; DLL4 PROTEIN, MOUSE; HYBRID PROTEIN; INDOLE DERIVATIVE; MEMBRANE PROTEIN; PYRROLE DERIVATIVE; REGN421; SIGNAL PEPTIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT DURATION; TUMOR BLOOD FLOW; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CHEMISTRY; DRUG SCREENING; HUMAN; KIDNEY NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911892712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112371     Document Type: Article

References (27)

1. National Cancer Institute at the National Institutes of Health. Available: http://www.cancer.gov/cancertopics/types/kidney. Accessed 2014 Jul 12
2. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanism of anti-tumour activity. Nat Rev Cancer 8: 579-591
3. Weis SM, Cheresh DA (2011) Box 3: Resistance to VEGF-targeted therapies. From: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: 1359-1370
4. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475
5. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, et al. (2007) Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: 4201-4208
6. Ioffe E, Burova E, Nandor S, Bai Y, Rudge JS, et al. (2012) Comparison of the effects of aflibercept (VEGF Trap) and small molecule kinase inhibitors on tumors and normal organs in mouse models. In: Proceedings of the 103rd Annual Meeting of the AACR 2012 Mar 31-Apr 4; Chicago, IL; Abstract 1023
7. Gaya A, Tse V (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38: 484-493
8. Bridges E, Oon CE, Harris A (2011) Notch regulation of tumor angiogenesis. Future Oncol 7: 569-588
9. Kuhnert F, Kirshner JR, Thurston G (2011) Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 3: 20
10. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037
11. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, et al. (2005) Upregulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8690-8697
12. Aparicio LM, Villaamil VM, Gallego GA, Cainzos IS, Campelo RG, et al. (2011) Expression of Notch1 to-4 and their ligands in renal cell carcinoma: a tissue microarray study. Cancer Genomics Proteomics 8: 93-101
13. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, et al. (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9: 1525-1535
14. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, et al. (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463: E6-7
15. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, et al. (2006) Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia 8: 534-542
16. Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, et al. (2012) Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Mol Cancer Ther 11: 383-392
17. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, et al. (2006) Inhibition of Dll4 signaling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087
18. Li JL, Sainson RC, Oon CE, Turley H, Leek R, et al. (2011) DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 71: 6073-6083
19. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, et al. (2011) Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 17: 372-381
20. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, et al. (2010) Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 176: 2019-2028
21. Hu W, Lu C, Dong HH, Huang J, Shen DY, et al. (2011) Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71: 6030-6039
22. Zhang JX, Cai MB, Wang XP, Duan LP, Shao Q, et al. (2013) Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol 30: 390
23. Gurney A, Hoey T (2011) Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vasc Cell 3: 18
24. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, et al. (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5: 168-177
25. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, et al. (2013) Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 19: 1972-1980
26. Yan M (2011) Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell 3: 17
27. Li JL, Jubb AM, Harris AL (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol 6: 1099-1103